CMMB
Chemomab Therapeutics Ltd. [CMMB] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CMMB Stock Summary
Top 10 Correlated ETFs
CMMB
Top 10 Correlated Stocks
CMMB
In the News
Chemomab Therapeutics Ltd. (CMMB) Q1 2023 Earnings Call Transcript
Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q1 2023 Earnings Conference Call May 11, 2023 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Adi Mor - Co-Founder and Chief Scientific Officer Matt Frankel - Chief Medical Officer, Vice President of Drug Development Don Marvin - Chief Financial Officer, Executive Vice President & Chief Operating Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Operator Greetings, and welcome to Chemomab Therapeutics First Quarter 2023 Earnings Call and Corporate Update.
Chemomab to Present at the Oppenheimer 33rd Annual Healthcare Conference
TEL AVIV, Israel , March 6, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday March 15, 2023.
Chemomab (CMMB) Stock Gains 30% on FDA Clearance
There's potentially positive news for the medical community as well as investors of Chemomab (NASDAQ: CMMB ) today. CMMB stock is moving higher because Chemomab has good news on the regulatory front, plus the company expects to move forward with important clinical research.
Chemomab Therapeutics stock soars after FDA clears IND for SSc treatment
Shares of Chemomab Therapeutics Ltd. CMMB, -0.51% shot up 46.9% in premarket trading Tuesday, after the Israel-based biotechnology company said the U.S. Food and Drug Administration cleared its Investigational New Drug (IND) application to evaluate its systemic sclerosis (SSc) treatment, CM-101.
Chemomab Therapeutics Ltd. (CMMB) Q3 2022 Earnings Call Transcript
Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer Don Marvin - Chief Financial Officer, Executive Vice President and Chief Operating Officer Adi Mor - Co-Founder and Chief Scientific Officer David Weiner - Interim Chief Medical Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Operator Greetings, and welcome to Chemomab's Third Quarter 2022 Earnings Conference Call.
Chemomab Therapeutics to Present at Upcoming Scientific Conferences
TEL AVIV, Israel , Oct. 28, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the company will participate in several scientific conferences in November.
Chemomab Therapeutics Ltd. (CMMB) CEO Dale Pfost on Q2 2022 Results - Earnings Call Transcript
Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q2 2022 Earnings Conference Call August 12, 2022 8:00 AM ET CompanyParticipants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & Chief Executive Officer David Weiner - Interim Chief Medical Officer Conference Call Participants Operator Greetings Welcome to Chemomab Therapeutics 2022 Second Quarter Earnings Call.
Chemomab Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update
TEL AVIV, Israel , Aug. 1, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced the company will release its second quarter 2022 financial results and provide a business update on Friday, August 12, 2022 at 8:00 am Eastern Time.
Chemomab Therapeutics to Participate in H.C. Wainwright Global Investment Conference
TEL AVIV, Israel , May 18, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in the virtual portion of the H.C.
Chemomab Therapeutics Ltd. (CMMB) CEO Dale Pfost on Q1 2022 Results - Earnings Call Transcript
Chemomab Therapeutics Ltd. (NASDAQ:CMMB ) Q1 2022 Earnings Conference Call May 11, 2022 8:00 AM ET Company Participants Barbara Lindheim - Consulting Vice President Investor & Public Relations Dale Pfost - Chairman & CEO David Weiner - Interim CMO Don Marvin - CFO, COO & EVP Adi Mor - Co-Founder & Chief Scientific Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Jeff Jones - Oppenheimer Nathan Weinstein - Aegis Capital Operator Greetings and welcome to the Chemomab First Quarter 2022 Earnings Call.
CMMB Financial details
CMMB Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | |
| Net income per share | -0.54 | -1.21 | -2.43 | |
| Operating cash flow per share | -0.48 | -1.19 | -1.79 | |
| Free cash flow per share | -0.48 | -1.22 | -1.8 | |
| Cash per share | 1.06 | 5.9 | 3.51 | |
| Book value per share | 0.98 | 5.93 | 3.18 | |
| Tangible book value per share | 0.98 | 5.93 | 3.18 | |
| Share holders equity per share | 0.98 | 5.93 | 3.18 | |
| Interest debt per share | 0.04 | 0.04 | 0.05 | |
| Market cap | 304.56M | 71.58M | 36.41M | |
| Enterprise value | 293.31M | 56.73M | 23.11M | |
| P/E ratio | -51.36 | -5.69 | -1.32 | |
| Price to sales ratio | 0 | 0 | 0 | |
| POCF ratio | -58.1 | -5.78 | -1.79 | |
| PFCF ratio | -57.68 | -5.67 | -1.78 | |
| P/B Ratio | 28.19 | 1.16 | 1.01 | |
| PTB ratio | 28.19 | 1.16 | 1.01 | |
| EV to sales | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -49.31 | -4.6 | -0.81 | |
| EV to operating cash flow | -55.95 | -4.58 | -1.13 | |
| EV to free cash flow | -55.55 | -4.5 | -1.13 | |
| Earnings yield | -0.02 | -0.18 | -0.76 | |
| Free cash flow yield | -0.02 | -0.18 | -0.56 | |
| Debt to equity | 0.15 | 0.05 | 0.19 | |
| Debt to assets | 0.13 | 0.04 | 0.16 | |
| Net debt to EBITDA | 1.89 | 1.2 | 0.47 | |
| Current ratio | 9 | 23.66 | 6.18 | |
| Interest coverage | 0 | -111.41 | -80.83 | |
| Income quality | 0.88 | 0.99 | 0.74 | |
| Dividend Yield | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.02 | 0 | |
| Capex to revenue | 0 | 0 | 0 | |
| Capex to depreciation | -1.58 | -7.03 | -1.17 | |
| Stock based compensation to revenue | 0 | 0 | 0 | |
| Graham number | 3.45 | 12.72 | 13.19 | |
| ROIC | 0.54 | -0.38 | -1.95 | |
| Return on tangible assets | -0.48 | -0.2 | -0.64 | |
| Graham Net | 0.92 | 5.63 | 2.93 | |
| Working capital | 10.52M | 60.04M | 34.99M | |
| Tangible asset value | 10.8M | 61.47M | 36.22M | |
| Net current asset value | 10.17M | 59.8M | 34.9M | |
| Invested capital | 0.04 | 0.01 | 0.01 | |
| Average receivables | 0 | 126.5K | 319K | |
| Average payables | 0 | 714.5K | 1.51M | |
| Average inventory | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | |
| ROE | -0.55 | -0.2 | -0.76 | |
| Capex per share | 0 | -0.02 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.47 | -0.54 | -0.73 | -0.72 | -0.79 | |
| Operating cash flow per share | -0.33 | -0.5 | -0.46 | -0.5 | -0.65 | |
| Free cash flow per share | -0.33 | -0.5 | -0.46 | -0.5 | -0.65 | |
| Cash per share | 5.03 | 4.53 | 4.06 | 3.49 | 2.96 | |
| Book value per share | 5.02 | 4.54 | 3.9 | 3.17 | 2.53 | |
| Tangible book value per share | 5.02 | 4.54 | 3.9 | 3.17 | 2.53 | |
| Share holders equity per share | 5.02 | 4.54 | 3.9 | 3.17 | 2.53 | |
| Interest debt per share | 0.05 | -0.02 | 0.04 | 0.05 | -1.59 | |
| Market cap | 54.74M | 42.21M | 28.48M | 36.6M | 17.57M | |
| Enterprise value | 41.23M | 32.61M | 17.99M | 23.3M | -3.02M | |
| P/E ratio | -2.57 | -1.7 | -0.86 | -1.11 | -0.5 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -14.75 | -7.4 | -5.42 | -6.42 | -2.44 | |
| PFCF ratio | -14.7 | -7.39 | -5.38 | -6.42 | -2.44 | |
| P/B Ratio | 0.96 | 0.81 | 0.64 | 1.01 | 0.63 | |
| PTB ratio | 0.96 | 0.81 | 0.64 | 1.01 | 0.63 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -7.77 | -5.23 | -2.17 | -2.7 | 0.33 | |
| EV to operating cash flow | -11.11 | -5.72 | -3.42 | -4.09 | 0.42 | |
| EV to free cash flow | -11.07 | -5.71 | -3.4 | -4.08 | 0.42 | |
| Earnings yield | -0.1 | -0.15 | -0.29 | -0.23 | -0.5 | |
| Free cash flow yield | -0.07 | -0.14 | -0.19 | -0.16 | -0.41 | |
| Debt to equity | 0.06 | 0.09 | 0.13 | 0.19 | 0.25 | |
| Debt to assets | 0.06 | 0.08 | 0.11 | 0.16 | 0.2 | |
| Net debt to EBITDA | 2.55 | 1.54 | 1.26 | 1.54 | 2.28 | |
| Current ratio | 16.87 | 12.48 | 8.9 | 6.18 | 4.83 | |
| Interest coverage | -24.63 | 13.03 | -35.09 | -22.74 | 0.51 | |
| Income quality | 0.73 | 0.92 | 0.65 | 0.69 | 0.82 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.01 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -1.08 | -0.79 | -2.47 | -0.07 | -0.06 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 7.26 | 7.45 | 7.99 | 7.18 | 6.71 | |
| ROIC | -0.17 | -0.16 | -0.31 | -0.6 | 1.04 | |
| Return on tangible assets | -0.09 | -0.11 | -0.17 | -0.19 | -0.25 | |
| Graham Net | 4.83 | 4.34 | 3.72 | 2.92 | 2.39 | |
| Working capital | 55.82M | 50.44M | 43.25M | 34.99M | 26.78M | |
| Tangible asset value | 57.24M | 51.84M | 44.62M | 36.22M | 27.95M | |
| Net current asset value | 55.62M | 50.29M | 43.13M | 34.9M | 26.72M | |
| Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 1.06M | 2.52M | 2.68M | 1.36M | 727K | |
| Average payables | 1.41M | 1.46M | 1.34M | 1.47M | 1.95M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 20.62 | 13.49 | 0 | 22.05 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 4.36 | 6.67 | 0 | 4.08 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.09 | -0.12 | -0.19 | -0.23 | -0.31 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
CMMB Frequently Asked Questions
What is Chemomab Therapeutics Ltd. stock symbol ?
Chemomab Therapeutics Ltd. is a IL stock and trading under the symbol CMMB
What is Chemomab Therapeutics Ltd. stock quote today ?
Chemomab Therapeutics Ltd. stock price is $1.62 today.
Is Chemomab Therapeutics Ltd. stock public?
Yes, Chemomab Therapeutics Ltd. is a publicly traded company.
Company Profile
- Volume Average 39.45K
- Market Capitalization 17.9M
- Employee 20
- CEO Dr. Dale R. Pfost Ph.D.
- Headquarters Tel Aviv,IL
- IPO Date 2012-08-14
-
Website
https://www.chemomab.com 
Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was incorporated in 2011 and is based in Tel Aviv, Israel.
